Cytokinetics saw the highest growth of 1.1% in patent filings in April and 1.32% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.1% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Cytokinetics‘s patent filings and grants. Buy the databook here.
Cytokinetics has been focused on protecting inventions in United States(US) with eight publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 19% filings and 31% grants. The China(CN), United States(US), European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where Cytokinetics is filings its patents. Among the top granted patent authorities, Cytokinetics has 31% of its grants in United States(US), 19% in European Patent Office(EPO) and 6% in Australia(AU).
Bayer could be the strongest competitor for Cytokinetics
In terms of grant share, Cytokinetics stands in sixth position among its competitors. Bayer and Cytokinetics secured the top positions according to recent patent publication data.
Congestive heart failure (heart failure) related patents lead Cytokinetics portfolio followed by hypertrophic cardiomyopathy, and petrochemicals
Cytokinetics has highest number of patents in congestive heart failure (heart failure) followed by hypertrophic cardiomyopathy, petrochemicals, myocardial ischemia, and muscular dystrophy. For congestive heart failure (heart failure), nearly 6% of patents were filed and 7% of patents were granted in Q2 2024.
For comprehensive analysis of Cytokinetics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.